De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Novavax Beheer

Beheer criteriumcontroles 1/4

De CEO Novavax's is John Jacobs, benoemd in Jan2023, heeft een ambtstermijn van 1.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.30M, bestaande uit 9.1% salaris en 90.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.03% van de aandelen van het bedrijf, ter waarde $ 600.33K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 4.2 jaar.

Belangrijke informatie

John Jacobs

Algemeen directeur

US$7.3m

Totale compensatie

Percentage CEO-salaris	9.1%
Dienstverband CEO	1.8yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Analyse CEO-vergoeding

Hoe is John Jacobs's beloning veranderd ten opzichte van Novavax's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$294m
Mar 31 2024	n/a	n/a	-US$399m
Dec 31 2023	US$7m	US$663k	-US$545m

Compensatie versus markt: De totale vergoeding ($USD 7.30M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van John te vergelijken met de prestaties van het bedrijf.

CEO

John Jacobs (57 yo)

1.8yrs

Tenure

US$7,301,009

Compensatie

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Jacobs	President	1.8yrs	US$7.30m	0.030% $ 646.9k
John Trizzino	President & COO	less than a year	US$1.88m	0.018% $ 385.2k
James Kelly	Executive VP	3.2yrs	US$1.50m	0.0090% $ 196.3k
Mark Casey	Executive VP	less than a year	US$1.53m	geen gegevens
Richard Crowley	Executive VP & COO	1.8yrs	geen gegevens	geen gegevens
Robert Walker	Senior VP	less than a year	geen gegevens	geen gegevens
Troy Morgan	Senior VP	no data	geen gegevens	geen gegevens
Erika Trahan	Associate Director of Investor & Public Relations	6.5yrs	geen gegevens	geen gegevens
Ian Watkins	Executive VP & Chief Human Resources Officer	1.3yrs	geen gegevens	geen gegevens
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.8yrs	geen gegevens	geen gegevens
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.7yrs	geen gegevens	0.0089% $ 193.7k

1.7yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVAX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Jacobs	President	1.8yrs	US$7.30m	0.030% $ 646.9k
David Mott	Independent Director	4.3yrs	US$187.53k	0.032% $ 687.0k
Richard Douglas	Independent Director	14.8yrs	US$189.53k	0.027% $ 597.7k
Margaret McGlynn	Independent Director	3.8yrs	US$185.02k	0.0065% $ 142.5k
Gregg Alton	Independent Director	4yrs	US$175.28k	0.0065% $ 142.5k
Rachel King	Independent Director	5.9yrs	US$174.55k	0.012% $ 257.5k
Richard Rodgers	Independent Director	2yrs	US$191.78k	0.0065% $ 142.5k
James Young	Independent Chairman of the Board	14.5yrs	US$222.53k	0.039% $ 840.6k

4.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Novavax Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold US$384k worth of stock

President of Research & Development notifies of intention to sell stock

Novavax, Inc., Annual General Meeting, Jun 13, 2024

President of Research & Development exercised options and sold US$14k worth of stock

CEO & Director exercised options and sold US$171k worth of stock

Recent updates

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

New minor risk - Profitability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2025

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 11% to US$19.17

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Novavax: New Chapter, Questions Remain

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

Price target increased by 13% to US$21.60

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%